SCH 23390 dissociated from conventional neuroleptics in apomorphine climbing and primate acute dyskinesia models.
SCH 23390 induced only a negligible incidence of the acute dyskinetic syndrome, a predictor of neuroleptic-induced extrapyramidal liability, in squirrel monkeys. However, haloperidol-induced dyskinesias were potentiated by SCH 23390 and were blocked by the D-1 agonist, SKF 38393. When administered orally or intraperitoneally to mice, SCH 23390 showed a considerably wider dose separation than did conventional neuroleptics between antagonism of apomorphine climbing and antagonism of stereotyped sniffing. Clinically relevant distinctions may exist between D-1 and D-2 antagonists, with D-1 antagonists (exemplified by SCH 23390) showing lower, although possibly not negligible, potential to cause extrapyramidal side effects.
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology*; D001552:Benzazepines / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology; D002749:Chlorprothixene / Q000494:pharmacology; D004357:Drug Synergism; D004409:Dyskinesia, Drug-Induced; D006220:Haloperidol; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D012453:Saimiri; D013239:Stereotyped Behavior / Q000187:drug effects
D001552:Benzazepines; D001562:Benzimidazoles; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D002749:Chlorprothixene; D006220:Haloperidol; D008787:Metoclopramide; D001058:Apomorphine; D002746:Chlorpromazine; C015411:oxiperomide